Nesiritide
Natrecor (nesiritide) is a protein pharmaceutical. Nesiritide was first approved as Natrecor on 2001-08-10. It is used to treat paroxysmal dyspnea in the USA. It is known to target atrial natriuretic peptide receptor 1.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nesiritide recombinant
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NATRECOR | Scios | N-020920 DISCN | 2001-08-10 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2325 | Injection, nesiritide, 0.1 mg |
Clinical
Clinical Trials
72 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 5 | 13 | 11 | 9 | 3 | 37 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | 1 | 1 | 1 | 4 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 3 | — | 1 | — | 4 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | — | — | 3 | — | 3 |
| Cardio-renal syndrome | D059347 | 1 | 1 | — | 1 | — | 2 | ||
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 1 | 1 | 2 |
| Dyspnea | D004417 | HP_0002094 | R06.0 | — | — | — | 1 | — | 1 |
| Pulmonary edema | D011654 | EFO_1001134 | J81 | — | — | — | 1 | — | 1 |
| Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | 1 | 1 | 2 | — | 1 | 4 |
| Cardiopulmonary bypass | D002315 | 1 | 2 | 1 | — | — | 3 | ||
| Coronary disease | D003327 | — | 1 | 1 | — | — | 2 | ||
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 1 | 1 | — | — | 2 |
| Coronary artery bypass | D001026 | EFO_0003776 | — | 1 | 1 | — | — | 2 | |
| Paroxysmal dyspnea | D004418 | I50.1 | — | — | 1 | — | — | 1 | |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | — | — | 1 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | 1 | — | — | 1 |
| Death | D003643 | PATO_0001422 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 4 | 2 | — | — | 3 | 7 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | 1 | 2 | — | — | 2 | 4 |
| Asymptomatic diseases | D058070 | 1 | 1 | — | — | — | 1 | ||
| Heart transplantation | D016027 | EFO_0010673 | — | 1 | — | — | — | 1 | |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | 1 | — | — | — | 1 | |
| Left ventricular dysfunction | D018487 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | — | — | 2 |
| Hyperinsulinism | D006946 | HP_0000842 | E16.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Shock | D012769 | R57.1 | — | — | — | — | 1 | 1 | |
| Wounds and injuries | D014947 | T14.8 | — | — | — | — | 1 | 1 | |
| Ventricular dysfunction | D018754 | — | — | — | — | 1 | 1 | ||
| Postoperative complications | D011183 | — | — | — | — | 1 | 1 | ||
| Thoracic neoplasms | D013899 | — | — | — | — | 1 | 1 | ||
| Artificial respiration | D012121 | — | — | — | — | 1 | 1 | ||
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Pregnancy rate | D018873 | — | — | — | — | 1 | 1 |
Show 17 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NESIRITIDE |
| INN | nesiritide |
| Description | Natriuretic peptides B [Precursor] |
| Classification | Protein |
| Drug class | peptides: atrial natriuretic type substances |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 124584-08-3 |
| RxCUI | 19666 |
| ChEMBL ID | CHEMBL1201668 |
| ChEBI ID | — |
| PubChem CID | 16134381 |
| DrugBank | DB04899 |
| UNII ID | P7WI8UL647 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
NPR1
NPR1
Organism
Homo sapiens
Gene name
NPR1
Gene synonyms
ANPRA
NCBI Gene ID
Protein name
atrial natriuretic peptide receptor 1
Protein synonyms
ANP-A, ANPR-A, Atrial natriuretic peptide receptor type A, atrionatriuretic peptide receptor A, GC-A, Guanylate cyclase A, natriuretic peptide A type receptor, natriuretic peptide receptor A, natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A), NPR-A, testicular tissue protein Li 20
Uniprot ID
Mouse ortholog
Npr1 (18160)
atrial natriuretic peptide receptor 1 (P18293)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,168 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
295 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more